Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the completion of enrollment in the explore-CKD phase 2 trial for ...

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

Immunotherapeutics have transformed cancer outcomes. It is crucial that response patterns seen with them are assessed ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

Cabarrus County Schools have plenty of choices, with 16 programs at 31 schools and 32% of students in those programs.

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...